Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Complexities of TGF-β targeted cancer therapy.
Connolly EC, Freimuth J, Akhurst RJ. Connolly EC, et al. Int J Biol Sci. 2012;8(7):964-78. doi: 10.7150/ijbs.4564. Epub 2012 Jul 12. Int J Biol Sci. 2012. PMID: 22811618 Free PMC article. Review.
This review will describe pre-clinical and clinical data of four major classes of TGF-beta inhibitor, namely i) ligand traps, ii) antisense oligonucleotides, iii) receptor kinase inhibitors and iv) peptide aptamers. Long term dosing strategies with TGF-beta inhibitors may …
This review will describe pre-clinical and clinical data of four major classes of TGF-beta inhibitor, namely i) ligand traps, ii) antisense …
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles.
Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM. Daldrup-Link HE, et al. Clin Cancer Res. 2011 Sep 1;17(17):5695-704. doi: 10.1158/1078-0432.CCR-10-3420. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791632 Free PMC article.
CONCLUSION: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for long-term prognosis, related treatment decisions, and the evaluation of new immune-targeted therapies....
CONCLUSION: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for …